Abstract
In The Lancet Oncology, Tingyan Shi and colleagues1 report their findings from the SOC-1 trial, one of three randomised phase 3 trials of secondary debulking followed by platinum-based chemotherapy versus chemotherapy alone in patients with their first recurrence of platinum-sensitive ovarian cancer. Previously, DESKTOP III and GOG-0213 reported results of this treatment strategy in the same population. Similar to DESKTOP III, objective eligibility criteria were used to determine likelihood of surgical resectability.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call